SuppreMol GmbH
http://www.suppremol.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From SuppreMol GmbH
Swiss VC Launches New Fund With Orphan Drug Aspirations
Basel-based BioMedPartners has launched a new CHF75m venture capital fund, BioMedInvest III, boosting financing opportunities for startups and mid-sized biotechs in the sparse European market.
Deals Shaping The Medical Industry, April 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
Deal Watch: Endo Elbows In On Valeant’s Pursuit Of Salix
Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.
Baxter acquires SuppreMol for innovative approach to autoimmune disease
Baxter's Bioscience Business has acquired SuppreMol for €200m in what the privately-held German firm's CEO called "a good day for both companies."
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice